Effects of fluticasone furoate/vilantrol on on lung function, peripheral blood Th1/Th2 drift, GSH-PX, MDA and 8-OHdG levels in patients with acute exacerbation of COPD

doi:10.3877/cma.j.issn.1674-6902.2020.05.005

Abstract

Abstract:

Objective

To observe the effects of fluticasone furoate/vilantrol (FF/VI) on lung function, peripheral blood Th1/Th2 drift, glutathione peroxidase (GSH-PX), malondialdehyde (MDA) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD).

Methods

A total of 100 patients with acute exacerbation of COPD were selected from the hospital and randomly divided into two groups by number table method. The control group were given conventional treatment. On the basis, the experimental group were additionally treated with FF/VI. Lung function indexes [the ratio of residual volume to total lung capacity (RV/TLC%), the percentage of forced expiratory volume in one second in the predicted value (FEV₁%)], levels of GSH-PX, MDA and 8-OhdG and adverse reactions were compared between the two groups before and after treatment. 50 healthy people were selected and included in the health group at the same time. The situation of peripheral blood Th1/Th2 drift [interferon γ (INF-γ), interleukin 4 (IL-4) and IL-4/INF-γ] in the experimental group and the control group was analyzed.

Results

After treatment, the FEV₁% in the experimental group was significantly higher than that in the control group (P<0.05), and the RV/TLC% was significantly lower than that in the control group (P<0.05). Before treatment, INF-γ and IL-4 were significantly higher in the experimental group and the control group than in the healthy group (P<0.05), while INF-γ/IL-4 was significantly lower than the healthy group (P<0.05). After treatment, INF-γ and IL-4 in the experimental group and the control group decreased significantly (P<0.05), and INF-γ/IL-4 increased significantly (P<0.05). INF-γ and IL-4 in the experimental group were significantly lower than those in the control group (P<0.05), and INF-γ/IL-4 was significantly higher than the control group (P<0.05). After treatment, the GSH-PX level in the experimental group was significantly higher than that in the control group (P<0.05), and the levels of MDA and 8-OhdG were significantly lower than the control group (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05).

Conclusion

FF/VI can effectively regulate the peripheral blood Th1/Th2 drift in patients with acute exacerbation of COPD, improve the expression levels of GSH-PX, MDA and 8-OhdG, and enhance the immune capacity, with antioxidant effect. It also can promote the recovery of lung function.

Key words: Fluticasone furoate/vilantrol, Chronic obstructive pulmonary disease, Acute exacerbation, Lung function, Th1/Th2

Shengquan Wei, Hua Xue, Huijun Xue. Effects of fluticasone furoate/vilantrol on on lung function, peripheral blood Th1/Th2 drift, GSH-PX, MDA and 8-OHdG levels in patients with acute exacerbation of COPD[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(05): 602-606.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.05.005

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I05/602

Figures/Tables 3

References 31

1	Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline[J]. Eur Respir J, 2017, 49(3): 1600791.
2	任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
3	尚立芝，谢文英，张良芝，等. 爱罗咳喘宁对稳定期和急性加重期COPD抗炎作用及机制研究[J]. 中国实验方剂学杂志，2015, 21(1): 134-139.
4	Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD[J]. Thorax, 2016, 71(2): 118-125.
5	Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report[J]. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
6	Abdillahi SM, Bober M, Nordin S, et al. Collagen VI Is Upregulated in COPD and Serves Both as an Adhesive Target and a Bactericidal Barrier for Moraxella catarrhalis[J]. J Innate Immun, 2015, 7(5): 506-517.
7	蒋雪莲，钟　萍，黄成亮，等. 氧化应激反应标志物在慢性阻塞性肺疾病稳定期患者血清中的表达及意义[J]. 中国呼吸与危重监护杂志，2016, 15(6): 542-547.
8	蒋燕红，卢月飞，王建华，等. 无创辅助通气联合机械振动排痰及药物治疗COPD急性加重期Ⅱ型呼吸衰竭的临床观察[J]. 中国药房，2015, 26(17): 2399-2401.
9	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007)年修订版[J]. 中华结核和呼吸杂志，2007, 30(1): 8-17.
10	Harrison SL, Janaudis-Ferreira T, Brooks D, et al. Self-Management Following an Acute Exacerbation of COPD[J]. Chest, 2015, 147(3): 646-661.
11	Caillaud D, Chanez P, Escamilla R, et al. Asthma-COPD overlap syndrome (ACOS) vs 'pure' COPD: a distinct phenotype？[J]. Allergy, 2017, 72(1): 137-145.
12	Woodcock A, Boucot I, Leather DA, et al. Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability[J]. Eur Respir J, 2018, 51(2): 1701531.
13	杨　琛，魏鑫鑫，尹中普. 糠酸氟替卡松鼻用喷雾剂治疗变应性鼻炎的临床研究[J]. 中国药房，2017, 28(11): 1503-1506.
14	吴海洪，高芳蝶，詹洁坚. 噻托溴铵联合沙美特罗/氟替卡松治疗慢性阻塞性肺疾病的临床研究[J]. 中国临床药理学杂志，2015, 31(6): 412-414.
15	Girodet PO, Raherison C, Molimard M. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.[J]. N Engl J Med, 2016, 375(13): 2605-2606.
16	Mehta R, Pefani E, Beerahee M, et al. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD[J]. J Clin Pharmacol, 2018, 58(11): 1461-1457.
17	Siler TM, Kerwin E, Sousa AR, et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies[J]. Respir Med, 2015, 109(9): 1155-1163.
18	Syed YY. Fluticasone Furoate/Vilanterol: a Review of Its Use in Patients with Asthma[J]. Drugs, 2015, 75(4): 407-418.
19	Wolthers OD, Stone S, Bareille P, et al. Knemometry assessment of short-term growth in children with asthma receiving fluticasone furoate for 2 weeks: a randomized, placebo-controlled, crossover trial[J]. Clin Ther, 2017, 39(6): 1191-1199.
20	Azevedo DDP, Medeiros WM, Freitas FFMD, et al. High oxygen extraction and slow recovery of muscle deoxygenation kinetics after neuromuscular electrical stimulation in COPD patients[J]. Eur J Appl Physiol, 2016, 116(10): 1899-1910.
21	Echevarria C, Steer J, Heslop-Marshall K, et al. The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPD[J]. Thorax, 2017, 72(8): 686-693.
22	黄　慧，徐作军. 新型长效β2-受体激动剂维兰特罗对慢性阻塞性肺疾病患者的有效性和安全性研究[J]. 中华结核和呼吸杂志，2012, 35(12): 956.
23	孙世民，张　珠，王云雀. COPD急性加重期和稳定期血清炎性因子水平及其与肺功能的关系[J]. 中国全科医学，2014, 17(24): 2790-2793.
24	曹　雯，杜永成，李　毅，等. 烟雾暴露对支气管哮喘大鼠CCR7和Th1/Th2细胞因子表达的影响[J]. 中华医学杂志，2018, 98(28): 2264-2268.
25	Hirahara K, Nakayama T. CD₄⁺ T-cell subsets in inflammatory diseases：beyond the Th1/Th2 paradigm[J]. Int Immunol, 2016, 28(4): 163-171.
26	Zhang W, Pan Y, Gou P, et al. Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model[J]. Oncol Rep, 2018, 39(1): 280-288.
27	冯晓玲，项　珊，黄廷荣，等. 麻辛汤在豚鼠哮喘模型哮喘急性发作期的作用机理研究[J]. 时珍国医国药，2018, 29(6): 1347-1348.
28	王成阳，刘向国，彭青和，等. 六味补气胶囊对COPD急性加重患者Treg及Th1、Th2、Th17型细胞的影响[J]. 中华中医药杂志，2014, 29(6): 1978-1981.
29	刘　颖，敬　岳，郭丽丽，等. 固本止咳中药对COPD模型小鼠脾、胸腺指数及Th1/Th2失衡的影响[J]. 中华中医药杂志，2015, 30(2): 504-506.
30	赵启君，刘晓菊，曾晓丽，等. 细颗粒物对慢性阻塞性肺疾病小鼠肺组织Nrf2水平的影响及与氧化应激的关系[J]. 中华医学杂志，2016, 96(28): 2241-2245.
31	何　梅，于素娥，郑　玲，等. COPD急性加重期行呼吸康复的可行性及效果研究[J]. 中国全科医学，2015, 18(8): 881-884.

组　别	例数	时间	FEV₁%	RV/TLC%
研究组	55	治疗前	51.04±9.82	57.36±10.65
		治疗后	68.62±11.47^ab	41.86±7.12^ab
对照组	45	治疗前	50.36±9.71	56.90±10.43
		治疗后	61.38±10.25^a	48.12±8.34^a

组　别	例数	时间	FEV₁%	RV/TLC%
研究组	55	治疗前	51.04±9.82	57.36±10.65
		治疗后	68.62±11.47^ab	41.86±7.12^ab
对照组	45	治疗前	50.36±9.71	56.90±10.43
		治疗后	61.38±10.25^a	48.12±8.34^a

组　别	例数	时间	INF-γ(ng/L)	IL-4(ng/L)	INF-γ/IL-4
研究组	55	治疗前	241.76±40.98^c	141.58±7.23^c	1.72±0.31^c
		治疗后	123.68±20.47^abc	64.39±10.42^abc	1.97±0.35^c
对照组	45	治疗前	240.63±38.72^c	140.65±7.12^c	1.70±0.32^c
		治疗后	145.72±23.65^ac	73.60±11.57^ac	1.83±0.30^c
健康组	50		101.35±18.74	46.83±7.25	2.25±0.40

组　别	例数	时间	INF-γ(ng/L)	IL-4(ng/L)	INF-γ/IL-4
研究组	55	治疗前	241.76±40.98^c	141.58±7.23^c	1.72±0.31^c
		治疗后	123.68±20.47^abc	64.39±10.42^abc	1.97±0.35^c
对照组	45	治疗前	240.63±38.72^c	140.65±7.12^c	1.70±0.32^c
		治疗后	145.72±23.65^ac	73.60±11.57^ac	1.83±0.30^c
健康组	50		101.35±18.74	46.83±7.25	2.25±0.40

组　别	例数	时间	GSH-PX(U/ml)	MDA(nmol/ml)	8-OhdG(ng/ml)
研究组	55	治疗前	136.57±21.45	8.05±1.24	7.23±1.25
		治疗后	170.28±32.74^ab	5.13±0.98^ab	1.30±0.21^ab
对照组	45	治疗前	137.24±21.36	8.11±1.26	7.18±1.23
		治疗后	151.83±27.61^a	6.72±0.83^a	2.36±0.42^a

Please choose a citation manager

Content to export